Omnipaque 300 mg I/ml Solution for Injection. clinical trials

A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)

This study is looking at a new combination of medicines and a treatment called TACE for people with advanced liver cancer. It aims to see if this combination can stop the cancer from growing for at least 6 months and if it's safe.